CIK 0001540171 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Avalyn Pharma Inc.
Sign in to watch- Ticker
- AVLN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 452463191
- Phone
- (206) 707-0340
- Business address
- 105 W FIRST ST., BOSTON, MA, 02127
- Former names
- Genoa Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,701,004
- in 1 filing
Net −$6,701,004. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-30 | Carlson Douglas R Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +211,975 | 211,975 | ||
| 2026-04-30 | Lavelle Erin Director | Grant or award · Stock Option (Right to Buy) | +26,978 | 26,978 | ||
| 2026-04-29 | Golden Adam H. General Counsel | Grant or award · Stock Option (Right to Buy) | +254,891 | 254,891 | ||
| 2026-04-29 | Congleton Jon Director | Grant or award · Stock Option (Right to Buy) | +26,978 | 26,978 | ||
| 2026-04-29 | Turner Heather D Director | Grant or award · Stock Option (Right to Buy) | +26,978 | 26,978 | ||
| 2026-04-29 | Rhodes Melissa Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +211,975 | 211,975 | ||
| 2026-04-29 | Haviland Kate Director | Grant or award · Stock Option (Right to Buy) | +26,978 | 26,978 | ||
| 2026-04-29 | Lazarus Howard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +211,975 | 211,975 | ||
| 2026-04-29 | Baranowski Lyn Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +501,033 | 501,033 |
Page 3 of 3 · 49 trades